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Evidence has accumulated indicating that obesity is associated with a state of chronic, low-grade inﬂammation. Obese adipose
tissue is characterized by dynamic changes in cellular composition and function, which may be referred to as “adipose tissue
remodeling”. Among stromal cells in the adipose tissue, inﬁltrated macrophages play an important role in adipose tissue
inﬂammation and systemic insulin resistance. We have demonstrated that a paracrine loop involving saturated fatty acids
and tumor necrosis factor-α derived from adipocytes and macrophages, respectively, aggravates obesity-induced adipose tissue
inﬂammation. Notably, saturated fatty acids, which are released from hypertrophied adipocytes via the macrophage-induced
lipolysis, serve as a naturally occurring ligand for Toll-like receptor 4 complex, thereby activating macrophages. Such a sustained
interaction between endogenous ligands derived from parenchymal cells and pathogen sensors expressed in stromal immune cells
should lead to chronic inﬂammatory responses ranging from the basal homeostatic state to diseased tissue remodeling, which may
be referred to as “homeostatic inﬂammation”. We, therefore, postulate that adipose tissue remodeling may represent a prototypic
example of homeostatic inﬂammation. Understanding the molecular mechanism underlying homeostatic inﬂammation may lead
to the identiﬁcation of novel therapeutic strategies to prevent or treat obesity-related complications.
1.Introduction
Themetabolicsyndromeisaconstellationofvisceralfatobe-
sity, insulin resistance, atherogenic dyslipidemia, and hyper-
tension, which all independently increase the risk of athe-
rosclerotic diseases [1–5]. The adipose tissue secretes a num-
ber of bioactive substances or adipocytokines, and unbal-
anced production of pro- and anti-inﬂammatory adipocy-
tokines in obese adipose tissue may critically contribute to
many aspects of the metabolic syndrome [1–5]. Obesity is
now viewed as a state of systemic, chronic low-grade in-
ﬂammation [1–4]. In contrast to acute inﬂammation which
resolves by an active termination program, chronic inﬂam-
mation may involve persistent stress and/or impaired resolu-
tion process, thereby resulting in functional maladaptation
and tissue remodeling [6]. On the other hand, during the
courseofobesity, adipose tissueischaracterizedbyadipocyte
hypertrophy, followed by increased angiogenesis, immune
cell inﬁltration, and extracellular matrix overproduction
[1, 2, 7, 8], which may be referred to as adipose tissue re-
modeling.
Pathogen sensors or pattern-recognition receptors
(PRRs), which are important for the recognition of path-
ogen-associated molecular patterns (PAMPs) in innate im-
munity, are also capable of recognizing endogenous ligands,
damage-associated molecular patterns (DAMPs) or danger
signals (Figure 1)[ 6, 9, 10]. Interaction between endogenous
ligands and pathogen sensors may play a role in the basal ho-
meostatic state as well as diseased tissue remodeling, which
has been referred to as homeostatic inﬂammation [6, 11].
This paper summarizes the molecular mechanism and pa-
thophysiologic implication of adipose tissue remodeling as a
prototypic example of homeostatic inﬂammation.
2. Adipose TissueInﬂammation andAdipose
Tissue Remodeling
In addition to lipid-laden mature adipocytes, the adipose
tissue is composed of various stromal cells, including2 International Journal of Inﬂammation
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Figure 1: Adipose tissue inﬂammation as homeostatic inﬂammation. In innate immunity, exogenous ligands (pathogen-associated
molecular patterns; PAMPs) are sensed by pattern-recognition receptors (PRRs), thereby inducing inﬂammatory changes. On the other
hand, damage-associated molecular patterns (DAMPs) released from damaged or stressed cells and tissues can activate PRRs, thereby
inducing homeostatic inﬂammation ranging from the basal homeostatic state to diseased tissue remodeling. For instance, free fatty acids
(FFAs) released from hypertrophied adipocytes can report, as a danger signal, their diseased state to macrophages via Toll-like receptor 4
(TLR4) complex during the course of obesity. dsRNA, double-strand RNA; PGN, peptidoglycan; ATP, adenosine tri-phosphate; oxLDL,
oxidized low-density lipoprotein; HSP, heat shock protein; HMGB1, high-mobility group box-1.
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Figure 2: Molecular mechanism underlying adipose tissue inﬂammation. During the course of obesity, adipose tissue secretes several
chemotactic factors to induce macrophage inﬁltration into adipose tissue. Circulating monocytes migrate and inﬁltrate into adipose tissue
through adhesion process to endothelial cells. Macrophages enhance the inﬂammatory changes through the crosstalk with parenchymal
adipocytes. For example, the macrophage-derived tumor necrosis factor-α (TNFα) induces the release of saturated fatty acids from
adipocytes via lipolysis, which, in turn, induces inﬂammatory changes in macrophages via TLR4. Such a paracrine loop between adipocytes
and macrophages constitutes a vicious cycle, thereby further accelerating adipose tissue inﬂammation. TNF-R, TNFα receptor.International Journal of Inﬂammation 3
preadipocytes, endothelial cells, ﬁbroblasts, and immune
cells [12]. Obese adipose tissue exhibits functional and mor-
phological changes, thereby leading to unbalanced produc-
tion of pro- and anti-inﬂammatory adipocytokines [1, 2, 7,
8]. The morphological changes found in obese adipose tis-
suearereminiscentofthechronicinﬂammatoryresponsesin
atherosclerotic vascular walls termed vascular remodeling,
which arise from the complex interactions among vascular
endothelial cells, vascular smooth muscle cells, lymphocytes,
and monocyte-derived macrophages [4]. Vascular remodel-
ing is considered to be an adaptive process in response to
long-term changes in hemodynamic conditions and lipid
metabolism, thereby contributing to the pathophysiology of
vascular diseases [13]. Thus, the dynamic changes seen in
obese adipose tissue can be referred to as adipose tissue re-
modeling. Notably, macrophage inﬁltration and inﬂamma-
tion-related gene expression in the adipose tissue precedes
the development of insulin resistance in animal models [14,
15],suggestingthatmacrophagesshouldplayacentralrolein
adiposetissueremodeling.Itis,therefore,importanttoknow
the pathophysiologic role of macrophages inﬁltrated into the
adipose tissue during the course of adipose tissue remodel-
ing.
3. Macrophage Inﬁltration into
Obese Adipose Tissue
Evidence has accumulated that adipocytes per se secrete pro-
inﬂammatory cytokines and chemokines, such as tumor ne-
crosis factor-α (TNFα), interleukin-6 (IL-6), and monocyte
chemoattractant protein-1 (MCP-1), during the course of
adipocyte hypertrophy [1–3]. Increased production of che-
mokines in obese adipose tissue has been implicated in the
regulation of monocyte recruitment to adipose tissue [14].
The involvement of MCP-1/chemokine receptor 2 (CCR2)
pathway has been extensively studied as the mechanism un-
derlying macrophage inﬁltration into obese adipose tissue
(Figure 2)[ 16–19]. Moreover, several reports have suggested
the role of other chemotactic factors in obesity-induced ma-
crophage inﬁltration: osteopontin, angiopoietin-like protein
2(Angptl2), and CXCmotif chemokine ligand-14 (CXCL14)
(Figure 2)[ 20–22]. Inhibition of macrophage inﬁltration
into obese adipose tissue through genetic and/or pharmac-
ologic strategies has improved the dysregulation of adipocy-
tokine production, thereby leading to the amelioration of
obesity-induced adipose tissue inﬂammation and insulin re-
sistance. Indeed, macrophage inﬁltration and inﬂammation-
related gene expression in the adipose tissue precedes the de-
velopment of insulin resistance in animal models [14, 15].
Understanding the molecular mechanisms underlying in-
creased macrophage inﬁltration into obese adipose tissue
may lead to the identiﬁcation of novel therapeutic strategies
to prevent or treat obesity-induced adipose tissue inﬂamma-
tion.
4. InteractionbetweenAdipocytesand
Macrophages
The adipose tissue macrophages also represent a major
source of pro-inﬂammatory cytokines, which play important
roles in chronic inﬂammatory responses in obese adipose
tissue. Using an in vitro coculture system composed of ad-
ipocytes and macrophages, we have demonstrated that a
paracrine loop involving saturated fatty acids and TNFα
derived from adipocytes and macrophages, respectively,
establishes a vicious cycle that augments the inﬂamma-
tory changes (Figure 2)[ 23]. Among numerous cytokines
derivedfrominﬁltratedmacrophagesinobeseadiposetissue,
TNFα acts on TNF receptor in hypertrophied adipocytes,
thereby inducing pro-inﬂammatory cytokine production
and adipocyte lipolysis via nuclear factor-κB-(NF-κB-)
dependent and independent (possibly mitogen-activated
protein kinase- (MAPK-) dependent) mechanisms, respec-
tively [24]. On the other hand, saturated fatty acids released
fromadipocytesserveasanaturallyoccurringligandforToll-
like receptor 4 (TLR4) complex, which is essential for the
recognition of lipopolysaccharide (LPS), to induce NF-κB
activation in macrophages [24].
The interaction between adipocytes and macrophages
results in marked upregulation of pro-inﬂammatory adipo-
cytokines and signiﬁcant downregulation of anti-inﬂamma-
tory adipocytokines, which lead to development of obesity-
related complications in multiple organs, such as atheroscle-
rosis and hepatic steatosis [1–4]. For instance, adiponectin is
a well-established anti-inﬂammatory adipocytokine, which
is markedly downregulated in obese adipose tissue, and sup-
plementation of adiponectin in obese mice eﬀectively re-
verses insulin resistance in the skeletal muscle and liver [25,
26]. On the other hand, overproduction of MCP-1 induces
macrophage inﬁltration into the adipose tissue and directly
induces insulin resistance in the skeletal muscle and liver [17,
18, 27]. Thus, dysregulation of adipocytokine production as
aresultofinﬂammatorychangesintheadiposetissuemaybe
involved in the pathogenesis of metabolic derangements in
obesity.
5. Heterogeneityof Adipose Tissue
Macrophages
Recent studies have pointed to the phenotypic change of
macrophages in lean and obese adipose tissue; M1 or clas-
sically activated (pro-inﬂammatory) macrophages and M2
or alternatively activated (anti-inﬂammatory) macrophages
(Figure 3)[ 28]. Adipocytes in lean adipose tissue produce
humoral factors that induce M2 activation of macrophages,
such as interleukin-4 (IL-4) and interleukin-13 (IL-13), and
M2 activated macrophages release anti-inﬂammatory medi-
ators, such as interleukin (IL-10) [29]. On the other hand,
hypertrophied adipocytes secrete pro-inﬂammatory satu-
rated fatty acids, cytokines, and chemokines to induce M1
polarization of macrophages [29]. Activated M1 macro-
phages in turn produce pro-inﬂammatory cytokines and4 International Journal of Inﬂammation
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Figure 3: Regulation of macrophage polarity in adipose tissue. Recent evidence has also pointed to the heterogeneity of adipose tissue
macrophages, that is, M1 or classically activated (pro-inﬂammatory) macrophages and M2 or alternatively activated (anti-inﬂammatory)
macrophages. Under lean condition, adipocytes secrete factors that promote M2 activation of macrophages, such as interleukin-4 (IL) and
interleukin-13 (IL-13). M2 macrophages secrete anti-inﬂammatory mediators. On the other hand, adipocytes secrete pro-inﬂammatory
FFAs, chemokines, and cytokines under obese condition. Activated M1 macrophages produce large amounts of pro-inﬂammatory cytokines,
thereby accelerating inﬂammatory responses in adipose tissue through paracrine interaction between adipocytes and macrophages.
chemokines, thereby accelerating adipose tissue inﬂamma-
tion.
Wehaverecentlyidentiﬁedactivatingtranscriptionfactor
3 (ATF3), a member of ATF/cAMP response element-bind-
ing protein family of basic leucine zipper-type transcription
factors, as a target gene of saturated fatty acids/TLR4 sig-
naling in adipose tissue macrophages and found that ATF3
attenuates obesity-induced macrophage activation in obese
adipose tissue [30]. On the other hand, peroxisome prolif-
erator-activated receptor γ (PPARγ) and peroxisome pro-
liferator-activated receptor β/δ (PPARβ/δ) can stimulate M2
polarization of adipose tissue macrophages and thus sys-
temic insulin sensitivity [31–34]. Indeed, the activation of
PPARγ by pioglitazone, a thiazolidinedione class of insulin
sensitizer, improves the unbalanced M1/M2 phenotype of
adipose tissue macrophages in diet-induced obese mice [35].
Interestingly, circulating blood monocytes, precursors of in-
ﬁltrated macrophages to the site of chronic inﬂammation,
a l s oe x p r e s sb o t hM 1a n dM 2m a r k e r s[ 36, 37]. Moreover,
monocytes in obese mice and/or obese type 2 diabetic pa-
tients show signiﬁcantly higher expression of M1 markers
and lower expression of M2 markers relative to normal-
weight controls [36]. Thus, pioglitazone treatment improves
theunbalancedM1/M2phenotypeofmonocytes,whichmay
contribute to its antidiabetic and antiatherogenic eﬀect [36,
37].
Recent studies have found other molecules that regulate
macrophage polarization; that is, Jumonji domain contain-
ing-3 (Jmjd3) is essential for M2 activation through de-
methylation of interferon-regulatory factor 4 (IRF4) under
infectious condition [38], and interferon-regulatory factor 5
(IRF5) is crucial for conversion from M2 to M1 activation in
response to LPS [39]. It is interesting to know their impor-
tance in the regulation of macrophage polarization and plas-
ticity during the course of obesity. Modulating macrophage
activationstateinobeseadiposetissuewouldbeanovelther-
apeutic target to treat or prevent the progression of obesity-
induced complications such as diabetes and atherosclerosis.
6. Adipose TissueRemodeling andEctopic
LipidAccumulation
The adipose tissue is primarily anenergy reservoir that stores
fatty acids in the form of triglyceride, which is facilitated by
insulin. However, obesity induces insulin-resistant state and
inﬂammation in the adipose tissue, both of which lead to
increased fatty acid release from the adipose tissue [1, 23,
29]. Moreover, recent studies have suggested that increased
expression of genes related to ECM components and ﬁbrotic
changes in the adipose tissue from obese subjects and an-
imals [40–43]. It is reported that adipose tissue ﬁbrosis is
negatively correlated with adipocyte diameters in human ad-
ipose tissue [44], suggesting that increased ECM compo-
nents may limit adipose tissue expandability. Indeed, Khan
et al. reported that mice lacking collagen VI, which is ex-
pressed predominantly in the adipose tissue, exhibit the un-
inhibited adipose tissue expansion and substantial improve-
ments in whole-body energy homeostasis during a high-fat
diet feeding [43]. It is conceivable that the rigid extracel-
lular environment limits adipocyte expansion, and triggers
adipocyte cell death and inﬂammatory responses through
MAPK activation by increased shear stress and membrane
stretching [43, 44]. Recent evidence suggests that impaired
lipid storage in the adipose tissue may contribute to ectopic
lipid accumulation in the skeletal muscle, liver, and pancre-
atic β-cells, where lipotoxicity impairs their metabolic func-
tions [45–47]. This discussion supports the emerging view
that metabolic problems associated with obesity become
overt when adipose tissue cannot fully meet demands forInternational Journal of Inﬂammation 5
additional lipid storage in addition to the dysregulation of
adipocytokine production.
7. Adipose TissueRemodeling as
Homeostatic Inﬂammation
TLR4 is a pattern-recognition receptor essential for the rec-
ognition of LPS, which is reported to play an important role
inobesity-inducedadiposetissueinﬂammationandsystemic
glucose and lipid metabolism in vivo [24, 48–50]. In obese
adipose tissue, TLR4 expressed in macrophages is capable of
sensing saturated fatty acids (FAs) released from adipocytes
to induce chronic inﬂammatory responses [24, 51, 52], sug-
gesting that saturated fatty acids could be a danger signal.
On the other hand, free fatty acids (FFAs) are an important
energy source mobilized from triglycerides stored in the adi-
pose tissue, particularly under starvation conditions. Kosteli
et al. have recently suggested that FFAs released from adi-
pocytes during fasting recruit macrophages into the adipose
tissue, which may be involved in the regulation of local
lipid concentrations [53]. In this regard, FFAs, when released
physiologically during fasting or starvation via adipocyte li-
polysis, may be involved in the regulation of metabolic ho-
meostasis within the adipose tissue rather than a danger sig-
nal. Under overnutrition conditions, increased concentra-
tions of FFAs also activate inﬂammatory pathways to main-
tain adipose tissue homeostasis such as tissue repair and reg-
ulation of metabolism. When cellular and/or tissue stresses
are excessive and/or sustained and adaptive responses are no
longer possible, inﬂammatory responses are prolonged (i.e.,
chronic inﬂammation), thereby leading to diseased tissue re-
modeling [6].
Recently, we have reported that macrophage-inducible
C-type lectin (Mincle; also called Clec4e and Clecsf9), a
pathogen sensor for pathogenic fungi and Mycobacterium
tuberculosis, is induced in adipose tissue macrophages in
obesity at least partly through the saturated fatty acid/TLR4/
NF-κB pathway, thereby suggesting its pathophysiologic
role in obesity-induced adipose tissue inﬂammation [54].
Yamasaki et al. reported that Mincle serves as a receptor for
SAP130, a component of small nuclear ribonucleoprotein
released from damaged cells, to sense cell death and induce
pro-inﬂammatory cytokine production [55]. Since dead adi-
pocytesaresurroundedbymacrophagesin theadipose tissue
of obese humans and mice (crown-like structure) [7, 8, 56],
itisconceivablethatMincleplaysaroleinsensingadipocyte-
derived endogenous ligand(s) during adipocyte death.
The above discussion supports the concept that interac-
tion between endogenous ligands and pathogen sensors in
the adipose tissue involves multiple stages of adipose tissue
remodeling, ranging from normal metabolic homeostasis
to diseased tissue remodeling, which may be referred to as
homeostatic inﬂammation. It is interesting to identify other
endogenous danger signals and pathogen sensors that con-
tribute to the pathophysiology of adipose tissue inﬂamma-
tion.
8. Homeostatic Inﬂammation and Other
Metabolic Disorders
Recent evidence has provided new insight into the interac-
tion between endogenous ligands and pathogen sensors in a
variety of chronic inﬂammatory diseases such as atheroscle-
rosis, diabetes mellitus, malignant cancers, autoimmune dis-
eases, and even neurodegenerative diseases. Similar to the in-
teraction between saturated fatty acids and TLR4, oxidized
low-density lipoprotein (LDL), known as a ligand for the
scavengerreceptorCD36,isreportedtotriggerinﬂammatory
signaling through a newly identiﬁed heterodimer of TLR4
and TLR6 in macrophages [57] and also to trigger CD36-
TLR2-dependent apoptosis in macrophages under endoplas-
mic reticulum stress [58]. On the other hand, Schulthess et
al.reportedthatCXCmotif chemokineligand-10(CXCL10),
when upregulated in diabetic pancreatic islet, is capable of
bindingtoTLR4inβ cellsinpancreaticisletstoinduceapop-
tosis [59].
In Nod-like receptor family, the NACHT, LRR, and PYD
domain-containingprotein3(NLRP3)inﬂammasomeiswell
characterized. The NLRP3 inﬂammasome is a cytosolic pro-
tein complex consisting of the regulatory subunit NLRP3,
the adaptor protein apoptosis-associated speck-like protein
containing a caspase-recruitment domain (ASC) and the ef-
fector subunit caspase-1. It is activated by pathogen-derived
DNA and endogenous DAMPs such as components of ne-
crotic cells and damaged tissues [60, 61]. Several lines of ev-
idence have suggested that the NLRP3 inﬂammasome plays
an important role in the pathogenesis of obesity-related dis-
eases. NLRP3 deﬁcient mice show improved glucose toler-
ance and insulin sensitivity [62]. It is also reported that
ceramide and islet amyloid polypeptide (IAPP) activate as
danger signals for NLRP3 inﬂammasome in adipose tissue
macrophagesandpancreaticislets,respectively,whichresults
in insulin resistance [63–65]. In atherogenesis, it is reported
that crystalline cholesterol acts as an endogenous danger sig-
nalanditsdepositioninarteriesorelsewhereisanearlycause
ratherthanalateconsequenceofinﬂammation[66].Abetter
understanding of the molecular basis underlying homeo-
static inﬂammation would allow more eﬃcient multidisci-
plinary approach to and a better assessment of the metabolic
syndrome.
9. Concluding Remarks
Obesity may be viewed as a chronic low-grade inﬂammation
as well as a metabolic disease. Although considerable pro-
gress has been made in understanding the cellular and mo-
lecular events that are involved in acute inﬂammation caused
by infection, there is no clear understanding of their phys-
iological counterpart of the systemic chronic inﬂammatory
state, which could be referred as homeostatic inﬂammation.
The interaction between parenchymal and stromal cells
through a number of endogenous ligands and pathogen sen-
sors may contribute to inﬂammatory responses in obese adi-
pose tissue as well as other metabolic organs. Understanding6 International Journal of Inﬂammation
the molecular mechanism underlying adipose tissue remod-
eling as homeostatic inﬂammation may lead to novel ther-
apeutic strategies to prevent or treat obesity-related compli-
cations.
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